Drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma

Drug‐induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms following nivolumab and ipilimumab in a pediatric patient with melanoma

Drug‐induced hypersensitivity syndrome (DIHS) is a type of severe cutaneous adverse reaction (SCAR). DIHS typically occurs 2–6 weeks after initiation of the offending medication. We report a case of DIHS in a pediatric patient undergoing treatment of metastatic melanoma with nivolumab and ipilimumab...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric dermatology Vol. 39; no. 3; pp. 486 - 487
Main Authors: Aljundi, Nawar, Utz Petry, Sarah, Moossavi, Meena, Daveluy, Steven
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc 01-05-2022
Subjects:
Allergies
Blood diseases
Case reports
drug‐induced hypersensitivity syndrome
Eosinophilia
Hypersensitivity
Immunotherapy
Melanoma
Metastases
Monoclonal antibodies
Patients
Pediatrics
Side effects
Skin
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Drug‐induced hypersensitivity syndrome (DIHS) is a type of severe cutaneous adverse reaction (SCAR). DIHS typically occurs 2–6 weeks after initiation of the offending medication. We report a case of DIHS in a pediatric patient undergoing treatment of metastatic melanoma with nivolumab and ipilimumab.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0736-8046
1525-1470
DOI:10.1111/pde.14940